FDA Finalizes Guidance on Mandatory Cosmetics Recalls

2 min

On October 22, 2026, the U.S. Food and Drug Administration (FDA) issued final guidance explaining how it will exercise its mandatory cosmetics recall authority under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The guidance addresses when FDA may require a recall, the process it will follow, and expectations for industry compliance.

When May FDA Require a Recall?

FDA must determine that there is a reasonable probability that a cosmetic is adulterated or misbranded and a reasonable probability that use of or exposure to the cosmetic will cause serious adverse health consequences or death.

FDA will consider evidence, including inspection findings, testing results, serious adverse event data, and consumer and trade complaints. Testing may encompass raw materials, finished cosmetics, and environmental samples from manufacturing facilities. The agency will also consider data linking the product to disease or injury. FDA's assessment will account for the vulnerability of those who normally use or are exposed to the cosmetic, including infants, toddlers, older adults, pregnant women, and medically compromised individuals. 

How Does the Process Work?

FDA must first give the "responsible person"—the manufacturer, packer, or distributor whose name appears on the product label—an opportunity to voluntarily cease distribution and recall the cosmetic. If the responsible person fails to act within the time and manner FDA prescribes, FDA may order an immediate distribution stop. The responsible person must comply with the order but may request an informal hearing to challenge whether adequate evidence supports it. FDA will specify the deadline for requesting a hearing in its notice to the responsible person. If granted, the hearing must be held no later than 10 days after the order is issued.

After providing that opportunity, FDA may vacate the order, continue the distribution stop, or require a recall with notification, timing, and reporting requirements.

What Should Companies Do Now?

The guidance does not create new legal obligations, and FDA expects most cosmetics recalls to remain voluntary. Nevertheless, it underscores the importance of being prepared to evaluate and respond to safety concerns promptly.

We recommend reviewing procedures for escalating complaints and adverse events, assessing potential health hazards, and making recall decisions. Companies should also confirm that they can identify affected products, stop distribution, and coordinate communications with supply-chain partners. Given the short hearing timeline, promptly assembling the relevant testing, complaint, and medical information will be important to assessing—and, where appropriate, challenging—FDA's conclusions.

Venable's FDA team is ready and able to assist with recall preparedness, product safety assessments, and FDA recalls.